Header Logo

YASUHIRO OKI

TitleAssociate Professor
InstitutionMD Anderson
DepartmentLymphoma-Myeloma
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Cherng HJ, Alig SK, Oki Y, Nastoupil LJ, Fayad L, Neelapu SS, Turturro F, Hagemeister F, Craig AFM, Macaulay CW, Rodriguez MA, Lee HJ, McDonnell TJ, Flowers CR, Vega F, Green MR, Feng L, Kurtz DM, Alizadeh AA, Davis RE, Westin JR. A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL. Blood Adv. 2023 04 11; 7(7):1137-1145. PMID: 36375046; PMCID: PMC10111343.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    2. Yamada K, Iwata K, Yoshimura Y, Ota H, Oki Y, Mitani Y, Oki Y, Yamada Y, Yamamoto A, Ono K, Honda A, Kitai T, Tachikawa R, Kohara N, Tomii K, Ishikawa A. Predicting the Readmission and Mortality in Older Patients Hospitalized with Pneumonia with Preadmission Frailty. J Frailty Aging. 2023; 12(3):208-213. PMID: 37493381.
      Citations:    
    3. Westin J, Davis RE, Feng L, Hagemeister F, Steiner R, Lee HJ, Fayad L, Nastoupil L, Ahmed S, Rodriguez A, Fanale M, Samaniego F, Iyer SP, Nair R, Oki Y, Fowler N, Wang M, Ma MCJ, Vega F, McDonnell T, Pinnix C, Griffith D, Lu Y, Tewari S, Sun R, Scott DW, Flowers CR, Neelapu S, Green MR. Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma. J Clin Oncol. 2023 02 01; 41(4):745-755. PMID: 35952327; PMCID: PMC10489211.
      Citations:    
    4. Evens AM, Connors JM, Younes A, Ansell SM, Kim WS, Radford J, Feldman T, Tuscano J, Savage KJ, Oki Y, Grigg A, Pocock C, Dlugosz-Danecka M, Fenton K, Forero-Torres A, Liu R, Jolin H, Gautam A, Gallamini A. Older patients (aged =60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study. Haematologica. 2022 05 01; 107(5):1086-1094. PMID: 34162178; PMCID: PMC9052913.
      Citations: 2     Fields:    Translation:Humans
    5. Landsburg DJ, Barta SK, Ramchandren R, Batlevi C, Iyer S, Kelly K, Micallef IN, Smith SM, Stevens DA, Alvarez M, Califano A, Shen Y, Bosker G, Parker J, Soikes R, Martinez E, von Roemeling R, Martell RE, Oki Y. Fimepinostat (CUDC-907) in patients with relapsed/refractory diffuse large B cell and high-grade B-cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses. Br J Haematol. 2021 10; 195(2):201-209. PMID: 34341990.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    6. Kim WS, Oki Y, Kim SJ, Yoon SE, Ardeshna KM, Lin Y, Ruan J, Porcu P, Brammer JE, Jacobsen ED, Yoon DH, Suh C, Radford J, Budde LE, Kim JS, Bachy E, Lee HJ, Bollard CM, Jaccard A, Kang HJ, Inman S, Murray M, Combs KE, Lee DY, Advani R, Gunter KC, Rooney CM, Heslop HE, Suarez F. Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study. Ann Hematol. 2021 Oct; 100(10):2529-2539. PMID: 34304287.
      Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
    7. Johnston PB, Cashen AF, Nikolinakos PG, Beaven AW, Barta SK, Bhat G, Hasal SJ, De Vos S, Oki Y, Deng C, Foss FM. Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma. Exp Hematol Oncol. 2021 Feb 18; 10(1):15. PMID: 33602316; PMCID: PMC7893947.
      Citations: 8     
    8. Schaffer M, Chaturvedi S, Davis C, de Jong J, Aquino R, Oki Y, Fourneau N, Younes A, Balasubramanian S. Activity of ibrutinib plus R-CHOP in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib study. Cancer Treat Res Commun. 2020; 25:100235. PMID: 33188997.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    9. Janku F, Park H, Call SG, Madwani K, Oki Y, Subbiah V, Hong DS, Naing A, Velez-Bravo VM, Barnes TG, Hagemeister FB, Falchook GS, Karp DD, Wheler JJ, Piha-Paul SA, Garrido-Laguna I, Shpall EJ, Fayad LE, Neelapu SS, Meric-Bernstam F, Kurzrock R, Fanale MA. Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma. Clin Cancer Res. 2020 11 01; 26(21):5579-5587. PMID: 33055173.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    10. Huen A, Haverkos BM, Zain J, Radhakrishnan R, Lechowicz MJ, Devata S, Korman NJ, Pinter-Brown L, Oki Y, Barde PJ, Nair A, Routhu KV, Viswanadha S, Vakkalanka S, Iyer SP. Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K d/? Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma. Cancers (Basel). 2020 Aug 15; 12(8). PMID: 32824175; PMCID: PMC7463651.
      Citations: 9     
    11. Katsuragi S, Oki Y, Scholz C, Akai S, K?hn F, Gr?ger H. Dynamic kinetic resolution of a tertiary alcohol. Chem Commun (Camb). 2020 Mar 07; 56(19):2885-2888. PMID: 32037430.
      Citations: 1     Fields:    
    12. Hu B, Nastoupil LJ, Loghavi S, Westin JR, Thakral B, Fayad LE, Hagemeister F, Neelapu S, Samaniego F, Lee HJ, Wang ML, Fanale M, Fowler N, Oki Y. De novo CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era. Leuk Lymphoma. 2020 02; 61(2):328-336. PMID: 31533521.
      Citations: 1     Fields:    Translation:Humans
    13. Strati P, Nastoupil LJ, Davis RE, Fayad LE, Fowler N, Hagemeister FB, Kwak L, Oki Y, Wang M, Westin J, Ruben CE, Wesson ET, Piekarz R, Fanale MA, Lee HJ. A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas. Haematologica. 2020 01; 105(1):e26-e28. PMID: 31073068; PMCID: PMC6939506.
      Citations: 7     Fields:    Translation:HumansCellsCTClinical Trials
    14. Barta SK, Zain J, MacFarlane AW, Smith SM, Ruan J, Fung HC, Tan CR, Yang Y, Alpaugh RK, Dulaimi E, Ross EA, Campbell KS, Khan N, Siddharta R, Fowler NH, Fisher RI, Oki Y. Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2019 06; 19(6):356-364.e3. PMID: 31029646; PMCID: PMC7433797.
      Citations: 36     Fields:    Translation:HumansCTClinical Trials
    15. Becnel MR, Nastoupil LJ, Samaniego F, Davis RE, You MJ, Green M, Hagemeister FB, Fanale MA, Fayad LE, Westin JR, Wang M, Oki Y, Forbes SG, Feng L, Neelapu SS, Fowler NH. Lenalidomide plus rituximab (R2 ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial. Br J Haematol. 2019 06; 185(5):874-882. PMID: 30919940; PMCID: PMC6619290.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    16. Sugita S, Honda R, Morota T, Kameda S, Sawada H, Tatsumi E, Yamada M, Honda C, Yokota Y, Kouyama T, Sakatani N, Ogawa K, Suzuki H, Okada T, Namiki N, Tanaka S, Iijima Y, Yoshioka K, Hayakawa M, Cho Y, Matsuoka M, Hirata N, Hirata N, Miyamoto H, Domingue D, Hirabayashi M, Nakamura T, Hiroi T, Michikami T, Michel P, Ballouz RL, Barnouin OS, Ernst CM, Schröder SE, Kikuchi H, Hemmi R, Komatsu G, Fukuhara T, Taguchi M, Arai T, Senshu H, Demura H, Ogawa Y, Shimaki Y, Sekiguchi T, Müller TG, Hagermann A, Mizuno T, Noda H, Matsumoto K, Yamada R, Ishihara Y, Ikeda H, Araki H, Yamamoto K, Abe S, Yoshida F, Higuchi A, Sasaki S, Oshigami S, Tsuruta S, Asari K, Tazawa S, Shizugami M, Kimura J, Otsubo T, Yabuta H, Hasegawa S, Ishiguro M, Tachibana S, Palmer E, Gaskell R, Le Corre L, Jaumann R, Otto K, Schmitz N, Abell PA, Barucci MA, Zolensky ME, Vilas F, Thuillet F, Sugimoto C, Takaki N, Suzuki Y, Kamiyoshihara H, Okada M, Nagata K, Fujimoto M, Yoshikawa M, Yamamoto Y, Shirai K, Noguchi R, Ogawa N, Terui F, Kikuchi S, Yamaguchi T, Oki Y, Takao Y, Takeuchi H, Ono G, Mimasu Y, Yoshikawa K, Takahashi T, Takei Y, Fujii A, Hirose C, Nakazawa S, Hosoda S, Mori O, Shimada T, Soldini S, Iwata T, Abe M, Yano H, Tsukizaki R, Ozaki M, Nishiyama K, Saiki T, Watanabe S, Tsuda Y, Michel P, Schr?der SE, Komatsu G, M?ller TG, Barucci MA, Thuillet F. The geomorphology, color, and thermal properties of Ryugu: Implications for parent-body processes. Science. 2019 04 19; 364(6437):252. PMID: 30890587; PMCID: PMC7370239.
      Citations:    
    17. Pinnix CC, Dabaja BS, Milgrom SA, Smith GL, Abou Yehia Z, Nastoupil L, Romaguera J, Turturro F, Fowler N, Fayad L, Westin J, Neelapu S, Fanale MA, Rodriguez MA, Hagemeister F, Lee HJ, Oki Y, Wang M, Samaniego F, Chi L, Esmaeli B. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head Neck. 2019 May; 41(5):1546. PMID: 30990235.
      Citations: 1     Fields:    
    18. Milgrom SA, Elhalawani H, Lee J, Wang Q, Mohamed ASR, Dabaja BS, Pinnix CC, Gunther JR, Court L, Rao A, Fuller CD, Akhtari M, Aristophanous M, Mawlawi O, Chuang HH, Sulman EP, Lee HJ, Hagemeister FB, Oki Y, Fanale M, Smith GL. A PET Radiomics Model to Predict Refractory Mediastinal Hodgkin Lymphoma. Sci Rep. 2019 02 04; 9(1):1322. PMID: 30718585; PMCID: PMC6361903.
      Citations: 16     Fields:    Translation:HumansCells
    19. Chihara D, Oki Y, Fanale MA, Westin JR, Nastoupil LJ, Neelapu S, Fayad L, Fowler NH, Cheah CY. Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ? Ann Hematol. 2019 May; 98(5):1169-1176. PMID: 30617643.
      Citations: 3     Fields:    Translation:Humans
    20. Chihara D, Oki Y. NK-Cell Lymphomas. Cancer Treat Res. 2019; 176:163-184. PMID: 30596218.
      Citations:    Fields:    Translation:Humans
    21. An Y, Jiang W, Andraos TY, Reddy JP, Yehia ZA, Lloyd S, Duvic M, D'Souza NM, Milgrom SA, Pinnix CC, Oki Y, Smith GL, Wilson LD, Dabaja BS. Multi-institutional Investigation: Circulating CD4:CD8 ratio is a prognosticator of response to total skin electron beam radiation in mycosis fungoides. Radiother Oncol. 2019 02; 131:88-92. PMID: 30773193; PMCID: PMC6662194.
      Citations: 3     Fields:    Translation:HumansCells
    22. Jensen GL, Dabaja BS, Pinnix CC, Gunther JR, Huen A, Duvic M, Oki Y, Fanale M, Hosing C, Milgrom SA. Radiotherapy in Patients with Mycosis Fungoides and Central Nervous System Involvement. Case Rep Oncol. 2018 Sep-Dec; 11(3):721-728. PMID: 30519174; PMCID: PMC6276745.
      Citations:    
    23. Chihara D, Wong S, Feldman T, Fanale MA, Sanchez L, Connors JM, Savage KJ, Oki Y. Outcome of patients with relapsed or refractory anaplastic large cell lymphoma who have failed brentuximab vedotin. Hematol Oncol. 2019 Feb; 37(1):35-38. PMID: 30209819.
      Citations: 2     Fields:    Translation:Humans
    24. Strati P, Fanale MA, Oki Y, Turturro F, Fayad LE, Bartlett NL, Gladstone DE, Kasamon YL, Portlock CS, Wilson WH, Goy A, Younes A, Lee HJ. ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study. Haematologica. 2019 02; 104(2):e65-e67. PMID: 30190343; PMCID: PMC6355491.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    25. Flinn IW, Patel M, Oki Y, Horwitz S, Foss FF, Allen K, Douglas M, Stern H, Sweeney J, Kharidia J, Kelly P, Kelly VM, Kahl B. Duvelisib, an oral dual PI3K-d, ? inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study. Am J Hematol. 2018 11; 93(11):1311-1317. PMID: 30033575; PMCID: PMC6220789.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    26. Liang WS, Vergilio JA, Salhia B, Huang HJ, Oki Y, Garrido-Laguna I, Park H, Westin JR, Meric-Bernstam F, Fabrizio D, Miller VA, Stephens PJ, Fanale MA, Ross JS, Janku F. Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden. Oncologist. 2019 02; 24(2):219-228. PMID: 30108156; PMCID: PMC6369943.
      Citations: 12     Fields:    Translation:Humans
    27. Sheu T, Milgrom SA, Andraos TY, Gunther JR, Chi L, Nastoupil L, Fowler N, Oki Y, Fanale MA, Fayad LE, Hagemeister F, Neelapu SS, Medeiros LJ, Hosing C, Nieto Y, Ahmed S, Alousi AM, Dabaja B, Pinnix CC. Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapy. Adv Radiat Oncol. 2018 Oct-Dec; 3(4):639-646. PMID: 30370365; PMCID: PMC6200878.
      Citations: 3     
    28. Chihara D, Oki Y, Fanale MA, Westin JR, Nastoupil LJ, Neelapu S, Fayad L, Fowler NH, Cheah CY. Stage I Non-Hodgkin Lymphoma: difference in survival outcome by primary extranodal site of involvement. Br J Haematol. 2019 04; 185(2):334-338. PMID: 29978452.
      Citations: 3     Fields:    Translation:Humans
    29. Chihara D, Fowler NH, Oki Y, Fanale MA, Nastoupil LJ, Westin JR, Fayad LE, Neelapu SS, Cheah CY. Impact of histologic subtypes and treatment modality among patients with primary central nervous system lymphoma: a SEER database analysis. Oncotarget. 2018 Jun 22; 9(48):28897-28902. PMID: 29988979; PMCID: PMC6034756.
      Citations: 11     Fields:    
    30. Pinnix CC, Ng AK, Dabaja BS, Milgrom SA, Gunther JR, Fuller CD, Smith GL, Abou Yehia Z, Qiao W, Wogan CF, Akhtari M, Mawlawi O, Medeiros LJ, Chuang HH, Martin-Doyle W, Armand P, LaCasce AS, Oki Y, Fanale M, Westin J, Neelapu S, Nastoupil L. Positron emission tomography-computed tomography predictors of progression after DA-R-EPOCH for PMBCL. Blood Adv. 2018 06 12; 2(11):1334-1343. PMID: 29895624; PMCID: PMC5998935.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    31. Moustafa GAI, Oki Y, Akai S. Lipase-Catalyzed Dynamic Kinetic Resolution of C1 - and C2 -Symmetric Racemic Axially Chiral 2,2'-Dihydroxy-1,1'-biaryls. Angew Chem Int Ed Engl. 2018 08 06; 57(32):10278-10282. PMID: 29704286.
      Citations: 9     Fields:    
    32. Huang W, Medeiros LJ, Lin P, Wang W, Tang G, Khoury J, Konoplev S, Yin CC, Xu J, Oki Y, Li S. MYC/BCL2/BCL6 triple hit lymphoma: a study of 40 patients with a comparison to MYC/BCL2 and MYC/BCL6 double hit lymphomas. Mod Pathol. 2018 09; 31(9):1470-1478. PMID: 29785017.
      Citations: 8     Fields:    Translation:Humans
    33. Romaguera JE, Wang M, Feng L, Fayad LE, Hagemeister F, McLaughlin P, Rodriguez MA, Fanale M, Orlowski R, Kwak LW, Neelapu S, Oki Y, Pro B, Younes A, Samaniego F, Fowler N, Hartig K, Valentinetti M, Smith J, Ford P, Naig A, Medeiros LJ, Kantarjian HM, Goy A. Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma. Cancer. 2018 06 15; 124(12):2561-2569. PMID: 29723393.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    34. Hu B, Oki Y. Novel Immunotherapy Options for Extranodal NK/T-Cell Lymphoma. Front Oncol. 2018; 8:139. PMID: 29761078; PMCID: PMC5937056.
      Citations: 22     
    35. Ludmir EB, Milgrom SA, Pinnix CC, Gunther JR, Westin J, Oki Y, Fayad LE, Medeiros LJ, Dabaja BS, Nastoupil LJ. Primary breast diffuse large B-cell lymphoma: treatment strategies and patterns of failure. Leuk Lymphoma. 2018 12; 59(12):2896-2903. PMID: 29697005.
      Citations: 5     Fields:    Translation:Humans
    36. Pinnix CC, Huo J, Milgrom SA, Yehia ZA, Fanale M, Oki Y, Dabaja BS, Smith GL. Using benchmarked lung radiation dose constraints to predict pneumonitis risk: Developing a nomogram for patients with mediastinal lymphoma. Adv Radiat Oncol. 2018 Jul-Sep; 3(3):372-381. PMID: 30202805; PMCID: PMC6128097.
      Citations: 1     
    37. Strati P, Chihara D, Oki Y, Fayad LE, Fowler N, Nastoupil L, Romaguera JE, Samaniego F, Garg N, Feng L, Wesson ET, Ruben CE, Stafford MD, Nieto Y, Khouri IF, Hosing C, Horowitz SB, Kamble RT, Fanale MA. A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Haematologica. 2018 09; 103(9):e416-e418. PMID: 29622656; PMCID: PMC6119133.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    38. Pinnix CC, Wirth A, Milgrom SA, Andraos TY, Aristophanous M, Pham M, Hancock D, Ludmir EB, Gunther JR, Fanale MA, Oki Y, Nastoupil L, Chuang HH, Mikhaeel NG, Dabaja BS. Omitting cardiophrenic lymph nodes in the treatment of patients with Hodgkin lymphoma via modified involved-site radiation therapy. Leuk Lymphoma. 2018 11; 59(11):2650-2659. PMID: 29616834; PMCID: PMC6363900.
      Citations: 1     Fields:    Translation:Humans
    39. Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez MA, Wang M, Fowler NH, Davis RE, Medeiros LJ, Oki Y. The risk of central nervous system relapses in patients with peripheral T-cell lymphoma. PLoS One. 2018; 13(3):e0191461. PMID: 29538376; PMCID: PMC5851529.
      Citations: 10     Fields:    Translation:Humans
    40. Pinnix CC, Cella L, Andraos TY, Ayoub Z, Milgrom SA, Gunther J, Thosani S, Wogan C, Conson M, D'Avino V, Oki Y, Fanale M, Lee HJ, Neelapu S, Fayad L, Hagemeister F, Rodriguez MA, Nastoupil LJ, Nieto Y, Qiao W, Pacelli R, Dabaja B. Predictors of Hypothyroidism in Hodgkin Lymphoma Survivors After Intensity Modulated Versus 3-Dimensional Radiation Therapy. Int J Radiat Oncol Biol Phys. 2018 07 01; 101(3):530-540. PMID: 29681481; PMCID: PMC7189963.
      Citations: 10     Fields:    Translation:Humans
    41. Nieto Y, Thall PF, Ma J, Valdez BC, Ahmed S, Anderlini P, Popat U, Jones RB, Shpall EJ, Hosing C, Qazilbash M, Kebriaei P, Alousi A, Timmons M, Gulbis A, Myers A, Oki Y, Fanale M, Dabaja B, Pinnix C, Milgrom S, Champlin R, Andersson BS. Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma. Biol Blood Marrow Transplant. 2018 08; 24(8):1602-1609. PMID: 29501779; PMCID: PMC8212703.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    42. Pinnix CC, Dabaja BS, Milgrom SA, Smith GL, Abou Z, Nastoupil L, Romaguera J, Turturro F, Fowler N, Fayad L, Westin J, Neelapu S, Fanale MA, Rodriguez MA, Hagemeister F, Ju Lee H, Oki Y, Wang M, Samaniego F, Chi L, Esmaeli B. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head Neck. 2018 06; 40(6):1335. PMID: 29851218.
      Citations: 2     Fields:    
    43. Chihara D, Oki Y. Central Nervous System Involvement in Peripheral T Cell Lymphoma. Curr Hematol Malig Rep. 2018 02; 13(1):1-6. PMID: 29374824.
      Citations: 2     Fields:    Translation:Humans
    44. Milgrom SA, Pinnix CC, Chi TL, Vu TH, Gunther JR, Sheu T, Fowler N, Westin JR, Nastoupil LJ, Oki Y, Fayad LE, Neelapu S, Rodriguez MA, Hagemeister FB, Fanale MA, Lee HJ, Hosing C, Ahmed S, Nieto Y, Shpall EJ, Dabaja BS. Radiation Therapy as an Effective Salvage Strategy for Secondary CNS Lymphoma. Int J Radiat Oncol Biol Phys. 2018 04 01; 100(5):1146-1154. PMID: 29452771.
      Citations: 1     Fields:    Translation:Humans
    45. Reddy JP, Hernandez M, Gunther JR, Dabaja BS, Martin GV, Jiang W, Akhtari M, Allen PK, Atkinson BJ, Smith GL, Pinnix CC, Milgrom SA, Abou Yehia Z, Osborne EM, Oki Y, Lee H, Hagemeister F, Fanale MA. Pre-treatment neutrophil/lymphocyte ratio and platelet/lymphocyte ratio are prognostic of progression in early stage classical Hodgkin lymphoma. Br J Haematol. 2018 02; 180(4):545-549. PMID: 29271057.
      Citations: 12     Fields:    Translation:HumansCells
    46. Horwitz SM, Koch R, Porcu P, Oki Y, Moskowitz A, Perez M, Myskowski P, Officer A, Jaffe JD, Morrow SN, Allen K, Douglas M, Stern H, Sweeney J, Kelly P, Kelly V, Aster JC, Weaver D, Foss FM, Weinstock DM. Activity of the PI3K-d,? inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood. 2018 02 22; 131(8):888-898. PMID: 29233821; PMCID: PMC5824337.
      Citations: 80     Fields:    Translation:HumansCTClinical Trials
    47. Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J, ECHELON-1 Study Group, Ill?s ?. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. N Engl J Med. 2018 01 25; 378(4):331-344. PMID: 29224502; PMCID: PMC5819601.
      Citations: 168     Fields:    Translation:HumansCTClinical Trials
    48. Flinn IW, O'Brien S, Kahl B, Patel M, Oki Y, Foss FF, Porcu P, Jones J, Burger JA, Jain N, Kelly VM, Allen K, Douglas M, Sweeney J, Kelly P, Horwitz S. Duvelisib, a novel oral dual inhibitor of PI3K-d,?, is clinically active in advanced hematologic malignancies. Blood. 2018 02 22; 131(8):877-887. PMID: 29191916; PMCID: PMC6033052.
      Citations: 77     Fields:    Translation:HumansCTClinical Trials
    49. Strati P, Fowler N, Pina-Oviedo S, Medeiros LJ, Overman MJ, Romaguera JE, Nastoupil L, Wang M, Hagemeister FB, Rodriguez A, Oki Y, Westin J, Turturro F, Neelapu SS, Fayad L. Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP. Clin Lymphoma Myeloma Leuk. 2018 01; 18(1):e103-e108. PMID: 29196178.
      Citations: 1     Fields:    Translation:Humans
    50. Akhtari M, Milgrom SA, Pinnix CC, Reddy JP, Dong W, Smith GL, Mawlawi O, Abou Yehia Z, Gunther J, Osborne EM, Andraos TY, Wogan CF, Rohren E, Garg N, Chuang H, Khoury JD, Oki Y, Fanale M, Dabaja BS. Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation. Blood. 2018 01 04; 131(1):84-94. PMID: 29038339; PMCID: PMC5755043.
      Citations: 25     Fields:    Translation:Humans
    51. Brammer JE, Chihara D, Poon LM, Caimi P, de Lima M, Ledesma C, Rondon G, Ciurea SO, Nieto Y, Fanale M, Dabaja B, Maziarz RT, Champlin RE, Hosing C, Oki Y. Management of Advanced and Relapsed/Refractory Extranodal Natural Killer T-Cell Lymphoma: An Analysis of Stem Cell Transplantation and Chemotherapy Outcomes. Clin Lymphoma Myeloma Leuk. 2018 01; 18(1):e41-e50. PMID: 29277360; PMCID: PMC8224469.
      Citations: 5     Fields:    Translation:HumansCells
    52. Oki Y, Kelly KR, Flinn I, Patel MR, Gharavi R, Ma A, Parker J, Hafeez A, Tuck D, Younes A. CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial. Haematologica. 2017 11; 102(11):1923-1930. PMID: 28860342; PMCID: PMC5664396.
      Citations: 43     Fields:    Translation:HumansCTClinical Trials
    53. Milgrom SA, Pinnix CC, Chuang H, Oki Y, Akhtari M, Mawlawi O, Garg N, Gunther JR, Reddy JP, Smith GL, Rohren E, Hagemeister FB, Lee HJ, Fayad LE, Dong W, Osborne EM, Abou Yehia Z, Fanale M, Dabaja BS. Early-stage Hodgkin lymphoma outcomes after combined modality therapy according to the post-chemotherapy 5-point score: can residual pet-positive disease be cured with radiotherapy alone? Br J Haematol. 2017 11; 179(3):488-496. PMID: 28832956; PMCID: PMC5871231.
      Citations: 3     Fields:    Translation:Humans
    54. Sugiyama K, Kawanishi S, Oki Y, Kamiya M, Hanada R, Egi M, Akai S. Lipase-catalyzed asymmetric synthesis of naphtho[2,3-c]furan-1(3H)-one derivatives by a one-pot dynamic kinetic resolution/intramolecular Diels-Alder reaction: Total synthesis of (-)-himbacine. Bioorg Med Chem. 2018 04 01; 26(7):1378-1386. PMID: 28844401.
      Citations: 1     Fields:    Translation:Cells
    55. Hu B, Younes A, Westin JR, Turturro F, Claret L, Feng L, Fowler N, Neelapu S, Romaguera J, Hagemeister FB, Rodriguez MA, Samaniego F, Fayad LE, Copeland AR, Nastoupil LJ, Nieto Y, Fanale MA, Oki Y. Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma. Leuk Lymphoma. 2018 04; 59(4):863-870. PMID: 28792260.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    56. Jain P, Kanagal-Shamanna R, San Lucas FA, Nastoupil L, Romaguera J, Fayad L, Oki Y, Westin JR, Medeiros LJ, Wang M, Fowler N. Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors. Br J Haematol. 2018 09; 182(5):718-723. PMID: 28771675; PMCID: PMC5904008.
      Citations: 1     Fields:    Translation:Humans
    57. Smith GL, Duvic M, Yehia ZA, Allen P, Garg N, Suki T, Milgrom SA, Pinnix CC, Oki Y, Khoury JD, Dabaja BS. Effectiveness of low-dose radiation for primary cutaneous anaplastic large cell lymphoma. Adv Radiat Oncol. 2017 Jul-Sep; 2(3):363-369. PMID: 29114604; PMCID: PMC5605318.
      Citations: 2     
    58. Fanale MA, Cheah CY, Rich A, Medeiros LJ, Lai CM, Oki Y, Romaguera JE, Fayad LE, Hagemeister FB, Samaniego F, Rodriguez MA, Neelapu SS, Lee HJ, Nastoupil L, Fowler NH, Turturro F, Westin JR, Wang ML, McLaughlin P, Pinnix CC, Milgrom SA, Dabaja B, Horowitz SB, Younes A. Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma. Blood. 2017 07 27; 130(4):472-477. PMID: 28522441; PMCID: PMC5578726.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    59. Ho JC, Dabaja BS, Milgrom SA, Smith GL, Reddy JP, Mazloom A, Young KH, Deng L, Medeiros LJ, Dong W, Allen PK, Andraos TY, Fowler NH, Nastoupil LJ, Oki Y, Fayad LE, Turturro F, Neelapu SS, Westin J, Hagemeister FB, Rodriguez MA, Pinnix CC. Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma. Leuk Lymphoma. 2017 12; 58(12):2833-2844. PMID: 28482717; PMCID: PMC6042648.
      Citations: 5     Fields:    Translation:Humans
    60. Pinnix CC, Andraos TY, Dabaja B, Milgrom S, Smith G, Chihara D, Ng A, Fayad LE, Oki Y, Neelapu S, Westin J, Rodriguez MA, Nastoupil LJ. Diffuse large B-cell lymphoma in very elderly patients over 80 years old: Incorporating consolidative radiation therapy into management decisions. Adv Radiat Oncol. 2017 Jul-Sep; 2(3):370-380. PMID: 29114605; PMCID: PMC5605286.
      Citations: 1     
    61. Lee HJ, Romaguera JE, Feng L, Desai AP, Zhang L, Fanale M, Samaniego F, Hagemeister FB, Fayad LE, Rodriguez MA, Medeiros JL, Hartig K, Nomie K, Ahmed M, Badillo M, Ye H, Oki Y, Lin P, Nastoupil L, Westin J, Wang M. Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma. Oncologist. 2017 05; 22(5):549-553. PMID: 28408615; PMCID: PMC5423503.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    62. Jain P, Milgrom SA, Patel KP, Nastoupil L, Fayad L, Wang M, Pinnix CC, Dabaja BS, Smith GL, Yu J, Hu S, Bueso Ramos CE, Kanagal-Shamanna R, Medeiros LJ, Oki Y, Fowler N. Characteristics, management, and outcomes of patients with follicular dendritic cell sarcoma. Br J Haematol. 2017 08; 178(3):403-412. PMID: 28382648; PMCID: PMC5903684.
      Citations: 14     Fields:    Translation:Humans
    63. Pinnix CC, Dabaja BS, Milgrom SA, Smith GL, Abou Z, Nastoupil L, Romaguera J, Turturro F, Fowler N, Fayad L, Westin J, Neelapu S, Fanale MA, Rodriguez MA, Hagemeister F, Lee HJ, Oki Y, Wang M, Samaniego F, Chi L, Esmaeli B. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head Neck. 2017 06; 39(6):1095-1100. PMID: 28370694; PMCID: PMC6044206.
      Citations: 26     Fields:    Translation:Humans
    64. Nastoupil LJ, McLaughlin P, Feng L, Neelapu SS, Samaniego F, Hagemeister FB, Ayala A, Romaguera JE, Goy AH, Neal E, Wang M, Fayad L, Fanale MA, Oki Y, Westin JR, Rodriguez MA, Cabanillas F, Fowler NH. High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study. Br J Haematol. 2017 04; 177(2):263-270. PMID: 28340281; PMCID: PMC5901692.
      Citations: 5     Fields:    Translation:Humans
    65. Thakral B, Medeiros LJ, Desai P, Lin P, Yin CC, Tang G, Khoury JD, Hu S, Xu J, Loghavi S, Hu B, Oki Y, Li S. Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH. Eur J Haematol. 2017 Apr; 98(4):415-421. PMID: 28039906.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    66. Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez MA, Wang M, Fowler NH, Davis RE, Medeiros LJ, Hosing C, Nieto YL, Oki Y. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. Br J Haematol. 2017 03; 176(5):750-758. PMID: 27983760; PMCID: PMC5836501.
      Citations: 27     Fields:    Translation:Humans
    67. Milgrom SA, Jauhari S, Plastaras JP, Nieto Y, Dabaja BS, Pinnix CC, Smith GL, Allen PK, Lukens JN, Maity A, Oki Y, Fanale MA, Nasta SD. A multi-institutional analysis of peritransplantation radiotherapy in patients with relapsed/refractory Hodgkin lymphoma undergoing autologous stem cell transplantation. Cancer. 2017 Apr 15; 123(8):1363-1371. PMID: 27984652; PMCID: PMC5811230.
      Citations: 4     Fields:    Translation:Humans
    68. Bartlett NL, Smith MR, Siddiqi T, Advani RH, O'Connor OA, Sharman JP, Feldman T, Savage KJ, Shustov AR, Diefenbach CS, Oki Y, Palanca-Wessels MC, Uttarwar M, Li M, Yang J, Jacobsen ED. Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry. Leuk Lymphoma. 2017 07; 58(7):1607-1616. PMID: 27868471.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    69. Xu J, Oki Y, Saksena A, Desai P, Lin P, Tang G, Yin CC, You MJ, Thakral B, Medeiros LJ, Li S. CD30 expression and prognostic significance in R-EPOCH-treated patients with diffuse large B-cell lymphoma. Hum Pathol. 2017 02; 60:160-166. PMID: 27816715.
      Citations:    Fields:    Translation:Humans
    70. Milgrom SA, Dong W, Akhtari M, Smith GL, Pinnix CC, Mawlawi O, Rohren E, Garg N, Chuang H, Yehia ZA, Reddy JP, Gunther JR, Khoury JD, Suki T, Osborne EM, Oki Y, Fanale M, Dabaja BS. Chemotherapy Response Assessment by FDG-PET-CT in Early-stage Classical Hodgkin Lymphoma: Moving Beyond the Five-Point Deauville Score. Int J Radiat Oncol Biol Phys. 2017 02 01; 97(2):333-338. PMID: 28068241; PMCID: PMC6033266.
      Citations: 3     Fields:    Translation:HumansCells
    71. Wang XJ, Bueso-Ramos CE, Tang G, Wang S, Oki Y, Desai P, Khoury JD, Miranda RN, Tang Z, Reddy N, Li S. P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC/BCL2 expression in diffuse large B-cell lymphoma. Mod Pathol. 2017 02; 30(2):194-203. PMID: 27739436.
      Citations: 27     Fields:    Translation:Humans
    72. Shimizu C, Oki Y, Mitani Y, Tsuchiya Y, Nabeshima T. Moderate-dose Regular Lifelong Alcohol Intake Changes the Intestinal Flora, Protects against Aging, and Keeps Spatial Memory in the Senescence-accelerated Mouse Prone 8 (SAMP8) Model. J Pharm Pharm Sci. 2016 Oct - Dec; 19(4):430-447. PMID: 28057167.
      Citations: 6     Fields:    Translation:Animals
    73. Wilmas K, Duvic M, Oki Y. Atypical lymphoproliferative disorder-clinical and pathological features. Dermatol Online J. 2016 Sep 15; 22(9). PMID: 28329608.
      Citations:    Fields:    Translation:Humans
    74. Abou Yehia Z, Mikhaeel GN, Smith G, Pinnix CC, Milgrom SA, Tang C, Jiang W, Fanale MA, Oki Y, Shank JH, Horace T, Reddy J, Akhtari M, Gunther JR, Suki T, Allen PK, Turner S, Mawlawi O, Dabaja BS. Does Bleomycin Lung Toxicity Increase the Risk of Radiation Pneumonitis in Hodgkin Lymphoma? Int J Radiat Oncol Biol Phys. 2016 12 01; 96(5):951-958. PMID: 27742539.
      Citations: 2     Fields:    Translation:Humans
    75. Chihara D, Fowler NH, Oki Y, Fanale MA, Fayad LE, Westin JR, Hagemeister FB. Dose-Adjusted EPOCH-R and Mid-Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS Involvement. Br J Haematol. 2017 12; 179(5):851-854. PMID: 27502933; PMCID: PMC6063086.
      Citations: 6     Fields:    Translation:Humans
    76. Pinnix CC, Osborne EM, Chihara D, Lai P, Zhou S, Ramirez MM, Oki Y, Hagemeister FB, Rodriguez AM, Samaniego F, Fowler N, Romaguera JE, Turturro F, Fayad L, Westin JR, Nastoupil L, Neelapu SS, Cheah CY, Dabaja BS, Milgrom SA, Smith GL, Horace P, Milbourne A, Wogan CF, Ballas L, Fanale MA. Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During Pregnancy. JAMA Oncol. 2016 Aug 01; 2(8):1065-9. PMID: 27227654; PMCID: PMC7457973.
      Citations: 9     Fields:    Translation:Humans
    77. Chen Y, Neelapu S, Feng L, Bi W, Yang TH, Wang M, Fanale MA, Westin JR, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Fowler NH, McLaughlin P, Cabanillas F, Oki Y, Nastoupil LJ, Rodriguez A. Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum ?2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model. Br J Haematol. 2016 Oct; 175(2):290-299. PMID: 27448187.
      Citations: 12     Fields:    Translation:HumansCells
    78. Chihara D, Westin JR, Miranda RN, Cheah CY, Oki Y, Turturro F, Romaguera JE, Neelapu SS, Nastoupil LJ, Fayad LE, Rodriguez MA, Fowler NH, Orlowski RZ, Wang M, Hagemeister FB, Medeiros LJ, Fanale MA. Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma. Br J Haematol. 2017 11; 179(3):503-506. PMID: 27378601; PMCID: PMC5920532.
      Citations: 3     Fields:    Translation:Humans
    79. Chihara D, Westin JR, Oki Y, Ahmed MA, Do B, Fayad LE, Hagemeister FB, Romaguera JE, Fanale MA, Lee HJ, Turturro F, Samaniego F, Neelapu SS, Rodriguez MA, Fowler NH, Wang M, Davis RE, Nastoupil LJ. Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma. Cancer. 2016 Oct 15; 122(20):3145-3151. PMID: 27351173.
      Citations: 25     Fields:    Translation:Humans
    80. Cheah CY, Chihara D, Moskowitz AJ, Engert A, Jerkeman M, El-Galaly TC, Augustson B, Vose J, Bartlett NL, Villa D, Connors JM, Feldman T, Pinnix CC, Milgrom SA, Dabaja B, Oki Y, Fanale MA, Br?ckelmann PJ. Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration. Am J Hematol. 2016 09; 91(9):894-9. PMID: 27222367.
      Citations: 4     Fields:    Translation:Humans
    81. Nieto Y, Valdez BC, Thall PF, Jones RB, Wei W, Myers A, Hosing C, Ahmed S, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Shah N, Bashir Q, Alousi A, Oki Y, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BS. Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. Cancer. 2016 09 01; 122(17):2680-8. PMID: 27203405; PMCID: PMC4992444.
      Citations: 18     Fields:    Translation:Humans
    82. Medeiros LJ, Tang G, Wang SA, Ahmed S, Nieto Y, Hu S, Bhagat G, Oki Y, Patel KP, Routbort M, Luthra R, Fanale MA, Bueso-Ramos CE, Jorgensen JL, Vega F, Chen W, Hoehn D, Konoplev S, Milton DR, Wistuba I, Li S, You MJ, Young KH, Miranda RN, Yabe M. Prognostic Factors of Hepatosplenic T-cell Lymphoma: Clinicopathologic Study of 28 Cases. Am J Surg Pathol. 2016 May; 40(5):676-88. PMID: 26872013.
      Citations: 14     Fields:    Translation:HumansCells
    83. Cheah CY, Chihara D, Horowitz S, Sevin A, Oki Y, Zhou S, Fowler NH, Romaguera JE, Turturro F, Hagemeister FB, Fayad LE, Wang M, Neelapu SS, Nastoupil LJ, Westin JR, Rodriguez MA, Samaniego F, Anderlini P, Nieto Y, Fanale MA. Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes. Ann Oncol. 2016 07; 27(7):1317-23. PMID: 27091808; PMCID: PMC6357675.
      Citations: 10     Fields:    Translation:Humans
    84. Anderlini P, Saliba RM, Ledesma C, Plair T, Alousi AM, Hosing CM, Khouri IF, Nieto Y, Popat UR, Shpall EJ, Fanale MA, Hagemeister FB, Oki Y, Neelapu S, Romaguera JE, Younes A, Champlin RE. Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell?Transplantation for Relapsed and Refractory Hodgkin?Lymphoma. Biol Blood Marrow Transplant. 2016 07; 22(7):1333-1337. PMID: 27064056; PMCID: PMC5193224.
      Citations: 10     Fields:    Translation:Humans
    85. Younes A, Berdeja JG, Patel MR, Flinn I, Gerecitano JF, Neelapu SS, Kelly KR, Copeland AR, Akins A, Clancy MS, Gong L, Wang J, Ma A, Viner JL, Oki Y. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial. Lancet Oncol. 2016 05; 17(5):622-31. PMID: 27049457; PMCID: PMC5494693.
      Citations: 61     Fields:    Translation:HumansCTClinical Trials
    86. Kim SJ, Yoon DH, Jaccard A, Chng WJ, Lim ST, Hong H, Park Y, Chang KM, Maeda Y, Ishida F, Shin DY, Kim JS, Jeong SH, Yang DH, Jo JC, Lee GW, Choi CW, Lee WS, Chen TY, Kim K, Jung SH, Murayama T, Oki Y, Advani R, d'Amore F, Schmitz N, Suh C, Suzuki R, Kwong YL, Lin TY, Kim WS. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. Lancet Oncol. 2016 Mar; 17(3):389-400. PMID: 26873565.
      Citations: 115     Fields:    Translation:HumansCells
    87. Cheah CY, Chihara D, Ahmed M, Davis RE, Nastoupil LJ, Phansalkar K, Hagemeister FB, Fayad LE, Westin JR, Oki Y, Fanale MA, Romaguera JE, Wang ML, Lee H, Turturro F, Samaniego F, Rodriguez MA, Neelapu SS, Fowler NH. Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era. Ann Oncol. 2016 05; 27(5):895-901. PMID: 26802151.
      Citations: 7     Fields:    Translation:Humans
    88. Pinnix CC, Shah JJ, Chuang H, Costelloe CM, Medeiros LJ, Wogan CF, Reed V, Smith GL, Milgrom S, Patel K, Huo J, Turturro F, Romaguera J, Fayad L, Oki Y, Fanale MA, Westin J, Nastoupil L, Hagemeister FB, Rodriguez A, Qazilbash M, Shah N, Bashir Q, Ahmed S, Nieto Y, Hosing C, Rohren E, Dabaja B. Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review. Clin Lymphoma Myeloma Leuk. 2016 Mar; 16(3):122-8. PMID: 26795083; PMCID: PMC9754636.
      Citations: 5     Fields:    Translation:Humans
    89. Clemens MW, Medeiros LJ, Butler CE, Hunt KK, Fanale MA, Horwitz S, Weisenburger DD, Liu J, Morgan EA, Kanagal-Shamanna R, Parkash V, Ning J, Sohani AR, Ferry JA, Mehta-Shah N, Dogan A, Liu H, Thormann N, Di Napoli A, DiNapoli A, Lade S, Piccolini J, Reyes R, Williams T, McCarthy CM, Hanson SE, Nastoupil LJ, Gaur R, Oki Y, Young KH, Miranda RN. Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma. J Clin Oncol. 2016 Jan 10; 34(2):160-8. PMID: 26628470; PMCID: PMC4872006.
      Citations: 86     Fields:    Translation:Humans
    90. Wang ML, Lee H, Chuang H, Wagner-Bartak N, Hagemeister F, Westin J, Fayad L, Samaniego F, Turturro F, Oki Y, Chen W, Badillo M, Nomie K, DeLa Rosa M, Zhao D, Lam L, Addison A, Zhang H, Young KH, Li S, Santos D, Medeiros LJ, Champlin R, Romaguera J, Zhang L. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol. 2016 Jan; 17(1):48-56. PMID: 26640039.
      Citations: 65     Fields:    Translation:HumansCTClinical Trials
    91. Hosing C, Bassett R, Dabaja B, Talpur R, Alousi A, Ciurea S, Popat U, Qazilbash M, Shpall EJ, Oki Y, Nieto Y, Pinnix C, Fanale M, Maadani F, Donato M, Champlin R, Duvic M. Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution. Ann Oncol. 2015 Dec; 26(12):2490-5. PMID: 26416896; PMCID: PMC4855245.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    92. Shimizu C, Oki Y, Mitani Y, Nakamura T, Nabeshima T. Factors Affecting Ethanol-Induced Conditioned Place Preference and Locomotor Sensitization in Mice. Biol Pharm Bull. 2015; 38(12):1935-45. PMID: 26377735.
      Citations: 3     Fields:    Translation:Animals
    93. Takahashi K, Sivina M, Hoellenriegel J, Oki Y, Hagemeister FB, Fayad L, Romaguera JE, Fowler N, Fanale MA, Kwak LW, Samaniego F, Neelapu S, Xiao L, Huang X, Kantarjian H, Keating MJ, Wierda W, Fu K, Chan WC, Vose JM, O'Brien S, Davis RE, Burger JA. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. Br J Haematol. 2015 Dec; 171(5):726-35. PMID: 26358140; PMCID: PMC4715651.
      Citations: 28     Fields:    Translation:HumansCells
    94. Chihara D, Pro B, Loghavi S, Miranda RN, Medeiros LJ, Fanale MA, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Neelapu SS, Younes A, Fowler NH, Rodriguez MA, Wang M, Kwak LW, McLaughlin P, Dang NH, Oki Y. Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol. 2015 Nov; 171(4):509-16. PMID: 26260306.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    95. Oki Y, Fanale M, Romaguera J, Fayad L, Fowler N, Copeland A, Samaniego F, Kwak LW, Neelapu S, Wang M, Feng L, Younes A. Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma. Br J Haematol. 2015 Nov; 171(4):463-70. PMID: 26213141; PMCID: PMC5278973.
      Citations: 36     Fields:    Translation:HumansCTClinical Trials
    96. Nieto Y, Valdez BC, Thall PF, Ahmed S, Jones RB, Hosing C, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Alousi A, Shah N, Bashir Q, Liu Y, Oki Y, Hagemeister F, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BS. Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. Biol Blood Marrow Transplant. 2015 Nov; 21(11):1914-20. PMID: 26071868; PMCID: PMC4781754.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    97. Cheah CY, Nastoupil LJ, Neelapu SS, Forbes SG, Oki Y, Fowler NH. Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma. Blood. 2015 May 21; 125(21):3357-9. PMID: 25999447; PMCID: PMC5161005.
      Citations: 37     Fields:    Translation:HumansCTClinical Trials
    98. Pinnix CC, Dabaja B, Ahmed MA, Chuang HH, Costelloe C, Wogan CF, Reed V, Romaguera JE, Neelapu S, Oki Y, Rodriguez MA, Fayad L, Hagemeister FB, Nastoupil L, Turturro F, Fowler N, Fanale MA, Nieto Y, Khouri IF, Ahmed S, Medeiros LJ, Davis RE, Westin J. Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography. Int J Radiat Oncol Biol Phys. 2015 May 01; 92(1):113-21. PMID: 25863759; PMCID: PMC4418191.
      Citations: 13     Fields:    Translation:Humans
    99. Pinnix CC, Smith GL, Milgrom S, Osborne EM, Reddy JP, Akhtari M, Reed V, Arzu I, Allen PK, Wogan CF, Fanale MA, Oki Y, Turturro F, Romaguera J, Fayad L, Fowler N, Westin J, Nastoupil L, Hagemeister FB, Rodriguez MA, Ahmed S, Nieto Y, Dabaja B. Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2015 May 01; 92(1):175-82. PMID: 25863764; PMCID: PMC4418193.
      Citations: 43     Fields:    Translation:Humans
    100. Peng J, Zuo Z, Fu B, Oki Y, Tang G, Goswami M, Priyanka P, Muzzafar T, Medeiros LJ, Luthra R, Wang SA. Chronic myelomonocytic leukemia with nucleophosmin (NPM1) mutation. Eur J Haematol. 2016 Jan; 96(1):65-71. PMID: 25809997.
      Citations: 14     Fields:    Translation:Humans
    101. Oki Y, Neelapu SS, Fanale M, Kwak LW, Fayad L, Rodriguez MA, Wallace M, Klinger M, Carlton V, Kong K, Faham M, Younes A. Detection of classical Hodgkin lymphoma specific sequence in peripheral blood using a next-generation sequencing approach. Br J Haematol. 2015 Jun; 169(5):689-93. PMID: 25818067; PMCID: PMC5279064.
      Citations: 17     Fields:    Translation:HumansCells
    102. Oki Y, Younes A, Knickerbocker J, Samaniego F, Nastoupil L, Hagemeister F, Romaguera J, Fowler N, Kwak L, Westin J. Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma. Haematologica. 2015 Jul; 100(7):e272-4. PMID: 25820332; PMCID: PMC4486240.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    103. Karuturi M, Younes A, Fayad L, Kwak L, Pro B, Shah J, Oki Y, Simien R, Liboon MJ, Hutto T, Feng L, Horowitz S, Nieto Y, Anderlini P, Alousi A, Popat U, Medeiros LJ, Miranda R, Fanale M. Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma: results of a randomized phase II trial. Leuk Lymphoma. 2016 Feb; 57(2):445-447. PMID: 25804933; PMCID: PMC5215977.
      Citations: 3     Fields:    
    104. Tao R, Allen PK, Rodriguez A, Shihadeh F, Pinnix CC, Arzu I, Reed VK, Oki Y, Westin JR, Fayad LE, Medeiros LJ, Dabaja B. Benefit of consolidative radiation therapy for primary bone diffuse large B-cell lymphoma. Int J Radiat Oncol Biol Phys. 2015 May 01; 92(1):122-9. PMID: 25754633.
      Citations: 14     Fields:    Translation:Humans
    105. Jacobsen ED, Sharman JP, Oki Y, Advani RH, Winter JN, Bello CM, Spitzer G, Palanca-Wessels MC, Kennedy DA, Levine P, Yang J, Bartlett NL. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood. 2015 Feb 26; 125(9):1394-402. PMID: 25573987.
      Citations: 83     Fields:    Translation:HumansCTClinical Trials
    106. Cheah CY, Oki Y, Fanale MA. Novel treatments for T-cell lymphoma. Am Soc Clin Oncol Educ Book. 2015; e468-78. PMID: 25993211.
      Citations: 1     Fields:    Translation:Humans
    107. Cheah CY, Oki Y, Westin JR, Turturro F. A clinician's guide to double hit lymphomas. Br J Haematol. 2015 Mar; 168(6):784-95. PMID: 25529575.
      Citations: 22     Fields:    Translation:Humans
    108. Hughes CL, Yorio JT, Kovitz C, Oki Y. Treatment decisions in a man with Hodgkin lymphoma and Guillian-Barr? syndrome: a case report. J Med Case Rep. 2014 Dec 21; 8:455. PMID: 25528252; PMCID: PMC4307131.
      Citations: 2     Fields:    Translation:Humans
    109. Fowler NH, Davis RE, Rawal S, Nastoupil L, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Westin JR, Shah J, Orlowski RZ, Wang M, Turturro F, Oki Y, Claret LC, Feng L, Baladandayuthapani V, Muzzafar T, Tsai KY, Samaniego F, Neelapu SS. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol. 2014 Nov; 15(12):1311-8. PMID: 25439689; PMCID: PMC4370362.
      Citations: 89     Fields:    Translation:HumansCTClinical Trials
    110. Oki Y, Ewer MS, Lenihan DJ, Fisch MJ, Hagemeister FB, Fanale M, Romaguera J, Pro B, Fowler N, Younes A, Astrow AB, Huang X, Kwak LW, Samaniego F, McLaughlin P, Neelapu SS, Wang M, Fayad LE, Durand JB, Rodriguez MA. Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial. Clin Lymphoma Myeloma Leuk. 2015 Mar; 15(3):152-8. PMID: 25445468; PMCID: PMC4344896.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    111. Chihara D, Oki Y. Brentuximab vedotin for treatment of systemic T-cell lymphoma. Expert Opin Biol Ther. 2014 Oct; 14(10):1519-26. PMID: 25200691.
      Citations: 1     Fields:    Translation:Humans
    112. Oki Y, Buglio D, Zhang J, Ying Y, Zhou S, Sureda A, Ben-Yehuda D, Zinzani PL, Prince HM, Harrison SJ, Kirschbaum M, Johnston PB, Shen A, von Tresckow B, Younes A. Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression. Blood Cancer J. 2014 Aug 08; 4:e236. PMID: 25105535; PMCID: PMC4219471.
      Citations: 26     Fields:    Translation:HumansCellsCTClinical Trials
    113. Younes A, Morschhauser F, Flinn I, Friedberg JW, Hivert B, Westin J, Vermeulen J, Bandyopadhyay N, de Vries R, Balasubramanian S, Hellemans P, Smit JW, Fourneau N, Oki Y, Thieblemont C, Amorim S. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. Lancet Oncol. 2014 Aug; 15(9):1019-26. PMID: 25042202.
      Citations: 98     Fields:    Translation:HumansCTClinical Trials
    114. Westin JR, McLaughlin P, Romaguera J, Hagemeister FB, Pro B, Dang NH, Samaniego F, Rodriguez MA, Fayad L, Oki Y, Fanale M, Fowler N, Nastoupil L, Feng L, Loyer E, Younes A. Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 2014 Oct; 167(2):177-84. PMID: 25039868; PMCID: PMC5279071.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    115. Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L, Ahmed M, Rodriguez MA, Hagemeister FB, Fowler N, Wang M, Fanale MA, Nastoupil L, Samaniego F, Lee HJ, Dabaja BS, Pinnix CC, Medeiros LJ, Nieto Y, Khouri I, Kwak LW, Turturro F, Romaguera JE, Fayad LE, Westin JR. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol. 2014 Sep; 166(6):891-901. PMID: 24943107.
      Citations: 105     Fields:    Translation:Humans
    116. Dabaja BS, Hess K, Shihadeh F, Podoloff DA, Medeiros LJ, Mawlawi O, Arzu I, Oki Y, Hagemeister FB, Fayad LE, Reed VK, Kedir A, Wogan CF, Rodriguez A. Positron emission tomography/computed tomography findings during therapy predict outcome in patients with diffuse large B-cell lymphoma treated with chemotherapy alone but not in those who receive consolidation radiation. Int J Radiat Oncol Biol Phys. 2014 Jun 01; 89(2):384-91. PMID: 24721592.
      Citations: 3     Fields:    Translation:Humans
    117. Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, O'Connor OA, Siddiqi T, Kennedy DA, Oki Y. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood. 2014 May 15; 123(20):3095-100. PMID: 24652992; PMCID: PMC4425442.
      Citations: 99     Fields:    Translation:HumansCTClinical Trials
    118. Leventaki V, Manning JT, Luthra R, Mehta P, Oki Y, Romaguera JE, Medeiros LJ, Vega F. Indolent peripheral T-cell lymphoma involving the gastrointestinal tract. Hum Pathol. 2014 Feb; 45(2):421-6. PMID: 24439229.
      Citations: 13     Fields:    Translation:Humans
    119. Oki Y, Chuang H, Chasen B, Jessop A, Pan T, Fanale M, Dabaja B, Fowler N, Romaguera J, Fayad L, Hagemeister F, Rodriguez MA, Neelapu S, Samaniego F, Kwak L, Younes A. The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. Br J Haematol. 2014 Apr; 165(1):112-6. PMID: 24386943; PMCID: PMC5308126.
      Citations: 15     Fields:    Translation:Humans
    120. Westin J, Oki Y, Fayad L. Could treatment with R-HCVAD/R-MA as compared to R- CHOP truly result in improved outcomes for patients with high-risk diffuse large B cell lymphoma? - Response to Landsburg et?al. Br J Haematol. 2014 Apr; 165(1):146-7. PMID: 24329994.
      Citations: 2     Fields:    Translation:Humans
    121. Oki Y, Buglio D, Fanale M, Fayad L, Copeland A, Romaguera J, Kwak LW, Pro B, de Castro Faria S, Neelapu S, Fowler N, Hagemeister F, Zhang J, Zhou S, Feng L, Younes A. Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma. Clin Cancer Res. 2013 Dec 15; 19(24):6882-90. PMID: 24097867; PMCID: PMC4409814.
      Citations: 42     Fields:    Translation:HumansCTClinical Trials
    122. Oki Y, Westin JR, Vega F, Chuang H, Fowler N, Neelapu S, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale M, Younes A, Rodriguez MA, Orlowski RZ, Wang M, Ouzounian ST, Samaniego F, Fayad L. Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. Br J Haematol. 2013 Dec; 163(5):611-20. PMID: 24117234; PMCID: PMC5278952.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    123. Armand P, Oki Y, Neuberg DS, Faham M, Cummings C, Klinger M, Weng L, Bhattar S, Lacasce AS, Jacobsen ED, Davids MS, Jacobson C, Fisher DC, Brown JR, Fowler NH, Alma Rodriguez M, Wallace MJ, Neelapu SS, Rodig S, Younes A, Freedman AS. Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 2013 Oct; 163(1):123-6. PMID: 23795711.
      Citations: 36     Fields:    Translation:HumansCells
    124. Dabaja BS, Phan J, Mawlawi O, Medeiros LJ, Etzel C, Liang FW, Podoloff D, Oki Y, Hagemeister FB, Chuang H, Fayad LE, Westin JR, Shihadeh F, Allen PK, Wogan CF, Rodriguez MA. Clinical implications of positron emission tomography-negative residual computed tomography masses after chemotherapy for diffuse large B-cell lymphoma. Leuk Lymphoma. 2013 Dec; 54(12):2631-8. PMID: 23488661; PMCID: PMC3827734.
      Citations: 9     Fields:    Translation:Humans
    125. Oki Y, Younes A, Copeland A, Hagemeister F, Fayad LE, McLaughlin P, Shah J, Fowler N, Romaguera J, Kwak LW, Pro B. Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol. 2013 Jul; 162(1):138-41. PMID: 23590726.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    126. Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera J, Neelapu SS, Hagemeister F, Fanale M, Oki Y, Pro B, Shah J, Thomas S, Younes A, Hosing C, Zhang L, Newberry KJ, Desai M, Cheng N, Badillo M, Bejarano M, Chen Y, Young KH, Champlin R, Kwak L, Fayad L. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia. 2013 Sep; 27(9):1902-9. PMID: 23545991.
      Citations: 65     Fields:    Translation:HumansCTClinical Trials
    127. Fowler N, Oki Y. Developing novel strategies to target B-cell malignancies. Am Soc Clin Oncol Educ Book. 2013; 366-72. PMID: 23714549.
      Citations: 3     Fields:    Translation:HumansCells
    128. Oki Y, Kondo Y, Yamamoto K, Ogura M, Kasai M, Kobayashi Y, Watanabe T, Uike N, Ohyashiki K, Okamoto S, Ohnishi K, Tomita A, Miyazaki Y, Tohyama K, Mukai HY, Hotta T, Tomonaga M. Phase I/II study of decitabine in patients with myelodysplastic syndrome: a multi-center study in Japan. Cancer Sci. 2012 Oct; 103(10):1839-47. PMID: 22816487; PMCID: PMC7659334.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    129. Oki Y, Younes A. Brentuximab vedotin in systemic T-cell lymphoma. Expert Opin Biol Ther. 2012 May; 12(5):623-32. PMID: 22428917.
      Citations: 4     Fields:    Translation:Humans
    130. Oki Y, Copeland A, Romaguera J, Fayad L, Fanale M, Faria Sde C, Medeiros LJ, Ivy P, Younes A. Clinical experience with the heat shock protein-90 inhibitor, tanespimycin, in patients with relapsed lymphoma. Leuk Lymphoma. 2012 May; 53(5):990-2. PMID: 21988665.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    131. Oki Y, Copeland A, Hagemeister F, Fayad LE, Fanale M, Romaguera J, Younes A. Experience with obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma. Blood. 2012 Mar 01; 119(9):2171-2. PMID: 22383790.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    132. Younes A, Oki Y, McLaughlin P, Copeland AR, Goy A, Pro B, Feng L, Yuan Y, Chuang HH, Macapinlac HA, Hagemeister F, Romaguera J, Samaniego F, Fanale MA, Dabaja BS, Rodriguez MA, Dang N, Kwak LW, Neelapu SS, Fayad LE. Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood. 2012 May 03; 119(18):4123-8. PMID: 22371887; PMCID: PMC3359733.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    133. Sugiyama T, Hirose T, Nakashima M, Ishida K, Oki Y, Murata Y, Kusumoto S, Shirai T, Yamaoka T, Okuda K, Ohnishi T, Ohmori T, Adachi M. Evaluation of the efficacy and safety of the combination of gemcitabine and nedaplatin for elderly patients with advanced non-small-cell lung cancer. Oncology. 2011; 81(3-4):273-80. PMID: 22122886.
      Citations: 2     Fields:    Translation:Humans
    134. Younes A, Oki Y, Bociek RG, Kuruvilla J, Fanale M, Neelapu S, Copeland A, Buglio D, Galal A, Besterman J, Li Z, Drouin M, Patterson T, Ward MR, Paulus JK, Ji Y, Medeiros LJ, Martell RE. Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2011 Dec; 12(13):1222-8. PMID: 22033282; PMCID: PMC5042214.
      Citations: 61     Fields:    Translation:HumansCTClinical Trials
    135. Kato H, Yamamoto K, Taji H, Oki Y, Chihara D, Seto M, Kagami Y, Morishima Y. Interstitial pneumonia after autologous hematopoietic stem cell transplantation in B-cell non-hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2011 Dec; 11(6):483-9. PMID: 21978956.
      Citations: 3     Fields:    Translation:Humans
    136. Kato H, Yamamoto K, Oki Y, Ine S, Taji H, Chihara D, Kagami Y, Seto M, Morishima Y. Clinical value of flow cytometric immunophenotypic analysis for minimal residual disease detection in autologous stem-cell products of follicular and mantle cell lymphomas. Leukemia. 2012 Jan; 26(1):166-9. PMID: 21818114.
      Citations: 1     Fields:    Translation:HumansCells
    137. Chihara D, Oki Y, Matsuo K, Onoda H, Taji H, Yamamoto K, Morishima Y. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: analyses with competing risk regression model. Leuk Lymphoma. 2011 Dec; 52(12):2270-5. PMID: 21745170.
      Citations: 11     Fields:    Translation:Humans
    138. Oki Y, Copeland A, Younes A. Clinical development of panobinostat in classical Hodgkin's lymphoma. Expert Rev Hematol. 2011 Jun; 4(3):245-52. PMID: 21668391.
      Citations: 5     Fields:    Translation:Humans
    139. Chihara D, Oki Y, Onoda H, Taji H, Yamamoto K, Tamaki T, Morishima Y. High maximum standard uptake value (SUVmax) on PET scan is associated with shorter survival in patients with diffuse large B cell lymphoma. Int J Hematol. 2011 Apr; 93(4):502-508. PMID: 21512731.
      Citations: 30     Fields:    Translation:Humans
    140. Kato H, Kagami Y, Kodaira T, Oka S, Oki Y, Chihara D, Taji H, Yatabe Y, Nakamura T, Nakamura S, Seto M, Yamamoto K, Morishima Y. Nodal relapse after Helicobacter pylori eradication in a patient with primary localized gastric mucosa-associated lymphoid tissue lymphoma. Am J Gastroenterol. 2011 Mar; 106(3):549-51. PMID: 21378774.
      Citations: 1     Fields:    Translation:HumansCells
    141. Potts BC, Albitar MX, Anderson KC, Baritaki S, Berkers C, Bonavida B, Chandra J, Chauhan D, Cusack JC, Fenical W, Ghobrial IM, Groll M, Jensen PR, Lam KS, Lloyd GK, McBride W, McConkey DJ, Miller CP, Neuteboom ST, Oki Y, Ovaa H, Pajonk F, Richardson PG, Roccaro AM, Sloss CM, Spear MA, Valashi E, Younes A, Palladino MA. Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets. 2011 Mar; 11(3):254-84. PMID: 21247382; PMCID: PMC3712795.
      Citations: 83     Fields:    Translation:HumansAnimals
    142. Gallegos J, Castoro RJ, Chung W, Maegawa S, Oki Y, Kondo Y, Jelinek J, Shen L, Hartung H, Aplan PD, Czerniak BA, Liang S, Issa JP, Est?cio MR, Vallot C. Genome architecture marked by retrotransposons modulates predisposition to DNA methylation in cancer. Genome Res. 2010 Oct; 20(10):1369-82. PMID: 20716667; PMCID: PMC2945186.
      Citations: 49     Fields:    Translation:HumansCells
    143. Oki Y, Younes A. Does rituximab have a place in treating classic hodgkin lymphoma? Curr Hematol Malig Rep. 2010 Jul; 5(3):135-9. PMID: 20490723.
      Citations: 10     Fields:    Translation:Humans
    144. Kato H, Yamamoto K, Matsuo K, Oki Y, Taji H, Kuwatsuka Y, Seto M, Kagami Y, Morishima Y. Clinical impact and predisposing factors of delayed-onset neutropenia after autologous hematopoietic stem-cell transplantation for B-cell non-Hodgkin lymphoma: association with an incremental risk of infectious events. Ann Oncol. 2010 Aug; 21(8):1699-1705. PMID: 20172906.
      Citations: 2     Fields:    Translation:Humans
    145. Chihara D, Oki Y, Ine S, Kato H, Onoda H, Taji H, Kagami Y, Yamamoto K, Morishima Y. Primary gastric diffuse large B-cell Lymphoma (DLBCL): analyses of prognostic factors and value of pretreatment FDG-PET scan. Eur J Haematol. 2010 Jun; 84(6):493-8. PMID: 20148943.
      Citations: 11     Fields:    Translation:Humans
    146. Oki Y, Issa JP. Epigenetic mechanisms in AML - a target for therapy. Cancer Treat Res. 2010; 145:19-40. PMID: 20306243.
      Citations: 23     Fields:    Translation:HumansCells
    147. Shen L, Kantarjian H, Guo Y, Lin E, Shan J, Huang X, Berry D, Ahmed S, Zhu W, Pierce S, Kondo Y, Oki Y, Jelinek J, Saba H, Estey E, Issa JP. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol. 2010 Feb 01; 28(4):605-13. PMID: 20038729; PMCID: PMC2815995.
      Citations: 121     Fields:    Translation:HumansCells
    148. Kato H, Taji H, Ogura M, Kagami Y, Oki Y, Tsujimura A, Fuwa N, Kodaira T, Seto M, Yamamoto K, Morishima Y. Favorable consolidative effect of high-dose melphalan and total-body irradiation followed by autologous peripheral blood stem cell transplantation after rituximab-containing induction chemotherapy with in vivo purging in relapsed or refractory follicular lymphoma. Clin Lymphoma Myeloma. 2009 Dec; 9(6):443-8. PMID: 19951884.
      Citations: 1     Fields:    Translation:Humans
    149. Chihara D, Oki Y, Ine S, Yamamoto K, Kato H, Taji H, Kagami Y, Yatabe Y, Nakamura S, Morishima Y. Analysis of prognostic factors in peripheral T-cell lymphoma: prognostic value of serum albumin and mediastinal lymphadenopathy. Leuk Lymphoma. 2009 Dec; 50(12):1999-2004. PMID: 19860627.
      Citations: 12     Fields:    Translation:Humans
    150. Wang M, Oki Y, Pro B, Romaguera JE, Rodriguez MA, Samaniego F, McLaughlin P, Hagemeister F, Neelapu S, Copeland A, Samuels BI, Loyer EM, Ji Y, Younes A. Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009 Nov 01; 27(31):5213-8. PMID: 19770379.
      Citations: 25     Fields:    Translation:HumansCTClinical Trials
    151. Chihara D, Kagami Y, Oki Y, Kato H, Onoda H, Ine S, Taji H, Yamamoto K, Morishima Y. R-CHOP therapy for MALT lymphoma of the rectum. Eur J Haematol. 2010 Jan 01; 84(1):84-6. PMID: 19737307.
      Citations: 3     Fields:    Translation:Humans
    152. Stewart DJ, Issa JP, Kurzrock R, Nunez MI, Jelinek J, Hong D, Oki Y, Guo Z, Gupta S, Wistuba II. Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. Clin Cancer Res. 2009 Jun 01; 15(11):3881-8. PMID: 19470736.
      Citations: 52     Fields:    Translation:HumansCellsCTClinical Trials
    153. Oki Y, Yamamoto K, Kato H, Kuwatsuka Y, Taji H, Kagami Y, Morishima Y. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab. Eur J Haematol. 2008 Dec; 81(6):448-53. PMID: 18691256.
      Citations: 33     Fields:    Translation:Humans
    154. Oki Y, Kato H, Matsuo K, Kuwatsuka Y, Taji H, Yamamoto K, Kagami Y, Morishima Y. Prognostic value of serum soluble interleukin-2 receptor level in patients with diffuse large B cell lymphoma, treated with CHOP- or RCHOP-based therapy. Leuk Lymphoma. 2008 Jul; 49(7):1345-51. PMID: 18452099.
      Citations: 3     Fields:    Translation:Humans
    155. Oki Y, Younes A. Current role of gemcitabine in the treatment of Hodgkin lymphoma. Leuk Lymphoma. 2008 May; 49(5):883-9. PMID: 18452104.
      Citations: 5     Fields:    Translation:Humans
    156. Oki Y, Pro B, Fayad LE, Romaguera J, Samaniego F, Hagemeister F, Neelapu S, McLaughlin P, Goy A, Younes A. Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer. 2008 Feb 15; 112(4):831-6. PMID: 18085611.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    157. Oki Y, Jelinek J, Shen L, Kantarjian HM, Issa JP. Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia. Blood. 2008 Feb 15; 111(4):2382-4. PMID: 18055864; PMCID: PMC2234065.
      Citations: 32     Fields:    Translation:HumansCellsCTClinical Trials
    158. Oki Y, Ogura M, Kato H, Kikuchi A, Taji H, Kagami Y, Oshiro A, Tsujimura A, Yamamoto K, Morishima Y. Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Cancer Sci. 2008 Jan; 99(1):179-84. PMID: 17991293; PMCID: PMC11159101.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    159. Oki Y, Issa JP. Treatment options in advanced myelodysplastic syndrome, with emphasis on epigenetic therapy. Int J Hematol. 2007 Nov; 86(4):306-14. PMID: 18055336.
      Citations: 4     Fields:    Translation:HumansAnimals
    160. Oki Y, Georgakis GV, Migone TS, Kwak LW, Younes A. Elevated serum BLyS levels in patients with non-Hodgkin lymphoma. Leuk Lymphoma. 2007 Sep; 48(9):1869-71. PMID: 17786728.
      Citations: 3     Fields:    Translation:Humans
    161. Oki Y, Koike H, Iijima M, Mori K, Hattori N, Katsuno M, Nakamura T, Hirayama M, Tanaka F, Shiraishi M, Yazaki S, Nokura K, Yamamoto H, Sobue G. Ataxic vs painful form of paraneoplastic neuropathy. Neurology. 2007 Aug 07; 69(6):564-72. PMID: 17679675.
      Citations: 12     Fields:    Translation:HumansCells
    162. Huang X, Biswas S, Oki Y, Issa JP, Berry DA. A parallel phase I/II clinical trial design for combination therapies. Biometrics. 2007 Jun; 63(2):429-36. PMID: 17688495.
      Citations: 35     Fields:    Translation:Humans
    163. Oki Y, Younes A. Endothelial progenitor cells in non-Hodgkin's lymphoma. Haematologica. 2007 Apr; 92(4):433-4. PMID: 17488651.
      Citations: 1     Fields:    Translation:HumansCells
    164. Oki Y, Kantarjian HM, Gharibyan V, Jones D, O'brien S, Verstovsek S, Cortes J, Morris GM, Garcia-Manero G, Issa JP. Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. Cancer. 2007 Mar 01; 109(5):899-906. PMID: 17236224.
      Citations: 42     Fields:    Translation:HumansCellsCTClinical Trials
    165. Oki Y, Georgakis GV, Migone TS, Kwak LW, Younes A. Prognostic significance of serum B-lymphocyte stimulator in Hodgkin's lymphoma. Haematologica. 2007 Feb; 92(2):269-70. PMID: 17296586.
      Citations: 5     Fields:    Translation:Humans
    166. Oki Y, McLaughlin P, Fayad LE, Pro B, Mansfield PF, Clayman GL, Medeiros LJ, Kwak LW, Srivastava PK, Younes A. Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma. Cancer. 2007 Jan 01; 109(1):77-83. PMID: 17133412.
      Citations: 14     Fields:    Translation:Humans
    167. Oki Y, Aoki E, Issa JP. Decitabine--bedside to bench. Crit Rev Oncol Hematol. 2007 Feb; 61(2):140-52. PMID: 17023173.
      Citations: 66     Fields:    Translation:HumansCells
    168. Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, Faderl S, Bueso-Ramos C, Ravandi F, Estrov Z, Ferrajoli A, Wierda W, Shan J, Davis J, Giles F, Saba HI, Issa JP. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007 Jan 01; 109(1):52-7. PMID: 16882708.
      Citations: 243     Fields:    Translation:HumansCells
    169. Oki Y, Jelinek J, Beran M, Verstovsek S, Kantarjian HM, Issa JP. Mutations and promoter methylation status of NPM1 in myeloproliferative disorders. Haematologica. 2006 Aug; 91(8):1147-8. PMID: 16870548.
      Citations: 8     Fields:    Translation:HumansCells
    170. Shu J, Jelinek J, Chang H, Shen L, Qin T, Chung W, Oki Y, Issa JP. Silencing of bidirectional promoters by DNA methylation in tumorigenesis. Cancer Res. 2006 May 15; 66(10):5077-84. PMID: 16707430.
      Citations: 41     Fields:    Translation:HumansCells
    171. Oki Y, Issa JP. Review: recent clinical trials in epigenetic therapy. Rev Recent Clin Trials. 2006 May; 1(2):169-82. PMID: 18473969.
      Citations: 16     Fields:    Translation:HumansAnimalsCells
    172. Oki Y, Kantarjian HM, Zhou X, Cortes J, Faderl S, Verstovsek S, O'Brien S, Koller C, Beran M, Bekele BN, Pierce S, Thomas D, Ravandi F, Wierda WG, Giles F, Ferrajoli A, Jabbour E, Keating MJ, Bueso-Ramos CE, Estey E, Garcia-Manero G. Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center. Blood. 2006 Feb 01; 107(3):880-4. PMID: 16123215.
      Citations: 23     Fields:    Translation:HumansCells
    173. Oki Y, McLaughlin P, Pro B, Hagemeister FB, Bleyer A, Loyer E, Younes A. Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma. Cancer. 2005 Aug 15; 104(4):781-7. PMID: 15973667.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    174. Jelinek J, Oki Y, Gharibyan V, Bueso-Ramos C, Prchal JT, Verstovsek S, Beran M, Estey E, Kantarjian HM, Issa JP. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood. 2005 Nov 15; 106(10):3370-3. PMID: 16037387; PMCID: PMC1895065.
      Citations: 104     Fields:    Translation:Humans
    175. Oki Y, Younes A. Heat shock protein-based cancer vaccines. Expert Rev Vaccines. 2004 Aug; 3(4):403-11. PMID: 15270645.
      Citations: 25     Fields:    Translation:HumansAnimals
    176. Matsunaga N, Oki Y, Prigollini A. A case of QT-interval prolongation precipitated by azithromycin. N Z Med J. 2003 Nov 07; 116(1185):U666. PMID: 14615808.
      Citations: 26     Fields:    Translation:Humans
    177. Kami M, Kishi Y, Hamaki T, Kawabata M, Kashima T, Masumoto T, Oki Y, Tanaka Y, Sawada S, Machida U, Ohtomo K, Kanda Y, Hirai H, Mutou Y. The value of the chest computed tomography halo sign in the diagnosis of invasive pulmonary aspergillosis. An autopsy-based retrospective study of 48 patients. Mycoses. 2002 Oct; 45(8):287-94. PMID: 12572717.
      Citations: 6     Fields:    Translation:Humans
    178. Kishi Y, Kami M, Oki Y, Hamaki T, Kanda Y, Machida U, Miyakoshi S, Ueyama J, Morinaga S, Muto Y. Successful bone marrow transplantation for adult T-cell leukemia from a donor with oligoclonal proliferation of T-cells infected with human T-cell lymphotropic virus. Leuk Lymphoma. 2001 Aug; 42(4):819-22. PMID: 11697515.
      Citations: 3     Fields:    Translation:HumansCells
    179. Uzuki M, Sasano H, Muramatsu Y, Totsune K, Takahashi K, Oki Y, Iino K, Sawai T. Urocortin in the synovial tissue of patients with rheumatoid arthritis. Clin Sci (Lond). 2001 Jun; 100(6):577-89. PMID: 11352772.
      Citations: 11     Fields:    Translation:Humans
    180. Kobayashi H, Kato Y, Hakamada M, Hattori Y, Sato A, Shimizu N, Imamura A, Mihara H, Kato H, Oki Y, Morishita M, Miwa H, Nitta M. Malignant lymphoma of the bone associated with systemic sarcoidosis. Intern Med. 2001 May; 40(5):435-8. PMID: 11393419.
      Citations: 4     Fields:    Translation:HumansCells
    181. Oki Y, Kami M, Kishi Y, Ueyama JI, Honma S, Sugiyama T, Miyakoshi S, Kanda Y, Morinaga SI, Muto Y. Pneumocystis carinii pneumonia with an atypical granulomatous response in a patient with chronic lymphocytic leukemia. Leuk Lymphoma. 2001 Apr; 41(3-4):435-8. PMID: 11378559.
      Citations: 4     Fields:    Translation:Humans
    182. Muramatsu Y, Sugino N, Suzuki T, Totsune K, Takahashi K, Tashiro A, Hongo M, Oki Y, Sasano H. Urocortin and corticotropin-releasing factor receptor expression in normal cycling human ovaries. J Clin Endocrinol Metab. 2001 Mar; 86(3):1362-9. PMID: 11238533.
      Citations: 8     Fields:    Translation:HumansCells
    183. Hara S, Kami M, Miyakoshi S, Suzuki R, Takeuchi K, Seki T, Oki Y, Kishi Y, Morinaga S, Mutou Y. Central nervous system involvement in pyothorax-associated lymphoma: ring enhancement on CT scan. Ann Hematol. 2001 Mar; 80(3):174-7. PMID: 11320904.
      Citations: 2     Fields:    Translation:Humans
    184. Kishi Y, Kami M, Kogi M, Oki Y, Machida U, Kanda Y, Ueyama J, Morinaga S, Muto Y. A limitation of fluorescence in situ hybridization (FISH) assays targeting sex chromosomes for monitoring of early relapse after transplantation. Transplantation. 2001 Feb 27; 71(4):581-3. PMID: 11258443.
      Citations:    Fields:    Translation:HumansCells
    185. Muramatsu Y, Fukushima K, Iino K, Totsune K, Takahashi K, Suzuki T, Hirasawa G, Takeyama J, Ito M, Nose M, Tashiro A, Hongo M, Oki Y, Nagura H, Sasano H. Urocortin and corticotropin-releasing factor receptor expression in the human colonic mucosa. Peptides. 2000 Dec; 21(12):1799-809. PMID: 11150640.
      Citations: 49     Fields:    Translation:HumansCells
    186. Iwata H, Kami M, Kishi Y, Oki Y, Tanaka Y, Takeuchi K, Yamazaki I, Suzuki R, Morinaga S, Mutou Y. Limitations of the diagnostic criteria for minimally differentiated acute myeloid leukemia (AML-MO) Leukemia. 2000 Nov; 14(11):2013-4. PMID: 11069040.
      Citations: 1     Fields:    Translation:HumansCells
    187. Oki Y, Okubo M, Tanaka S, Nakanishi K, Kobayashi T, Murase T. Diabetes mellitus secondary to glycogen storage disease type III. Diabet Med. 2000 Nov; 17(11):810-2. PMID: 11131107.
      Citations: 10     Fields:    Translation:Humans
    188. Oki Y, Kishi Y, Kami M. Philadelphia chromosome-positive acute lymphoblastic leukemia in children. N Engl J Med. 2000 Oct 05; 343(14):1043; author reply 1043-4. PMID: 11023396.
      Citations:    Fields:    Translation:Humans
    189. Fruchter O. Philadelphia chromosome-positive acute lymphoblastic leukemia in children. N Engl J Med. 2000 Oct 05; 343(14):1043; author reply 1043-4. PMID: 11023395.
      Citations:    Fields:    Translation:Humans
    190. Urakami Y, Sano T, Begum S, Endo H, Kawamata H, Oki Y. Endoscopic characteristics of low-grade gastric mucosa-associated lymphoid tissue lymphoma after eradication of Helicobacter pylori. J Gastroenterol Hepatol. 2000 Oct; 15(10):1113-9. PMID: 11106089.
      Citations: 8     Fields:    Translation:HumansCells
    191. Kishi Y, Kami M, Oki Y, Kazuyama Y, Kawabata M, Miyakoshi S, Morinaga S, Suzuki R, Mori S, Muto Y. Donor lymphocyte infusion for treatment of life-threatening respiratory syncytial virus infection following bone marrow transplantation. Bone Marrow Transplant. 2000 Sep; 26(5):573-6. PMID: 11019850.
      Citations: 10     Fields:    Translation:Humans
    192. Iino K, Oki Y, Sasano H. A case of adrenocortical carcinoma associated with recurrence after laparoscopic surgery. Clin Endocrinol (Oxf). 2000 Aug; 53(2):243-8. PMID: 10931107.
      Citations: 3     Fields:    Translation:Humans
    193. Zhao DM, Xue HH, Chida K, Suda T, Oki Y, Kanai M, Uchida C, Ichiyama A, Nakamura H. Effect of erythromycin on ATP-induced intracellular calcium response in A549 cells. Am J Physiol Lung Cell Mol Physiol. 2000 Apr; 278(4):L726-36. PMID: 10749750.
      Citations: 13     Fields:    Translation:HumansCells
    194. Kishi Y, Oki Y, Machida U. Thalidomide in multiple myeloma. N Engl J Med. 2000 Mar 30; 342(13):975; author reply 975-6. PMID: 10744492.
      Citations: 3     Fields:    Translation:Humans
    195. Oki Y, Kami M, Muto Y. Long-term survival after bone marrow transplantation. N Engl J Med. 1999 Oct 28; 341(18):1394; author reply 1395. PMID: 10577087.
      Citations:    Fields:    Translation:Humans
    196. Yorozu A, Dokiya T, Oki Y. High-dose-rate brachytherapy boost following concurrent chemoradiotherapy for esophageal carcinoma. Int J Radiat Oncol Biol Phys. 1999 Sep 01; 45(2):271-5. PMID: 10487545.
      Citations: 8     Fields:    Translation:Humans
    197. Iwabuchi M, Oki Y, Nakamura H. Palliative chemotherapy for malignant pheochromocytoma: symptomatic palliation of two cases. Intern Med. 1999 May; 38(5):433-5. PMID: 10397082.
      Citations: 2     Fields:    Translation:Humans
    198. Yorozu A, Dokiya T, Oki Y, Suzuki T. Curative radiotherapy with high-dose-rate brachytherapy boost for localized esophageal carcinoma: dose-effect relationship of brachytherapy with the balloon type applicator system. Radiother Oncol. 1999 May; 51(2):133-9. PMID: 10435804.
      Citations: 5     Fields:    Translation:HumansPHPublic Health
    199. Kato H, Sakurai E, Morishita M, Oki Y, Watanabe K, Kawajiri T, Miyara H, Shanzhong Y, Nitta M, Inoue M. [Management of mycobacteriosis in general hospital without isolation ward for tuberculosis patients. 5. The management of the patients excreting tubercle bacilli in a university hospital without isolation ward for tuberculosis]. Kekkaku. 1999 Feb; 74(2):151-6. PMID: 10191611.
      Citations:    Fields:    Translation:HumansPHPublic Health
    200. Iino K, Sasano H, Oki Y, Andoh N, Shin RW, Kitamoto T, Takahashi K, Suzuki H, Tezuka F, Yoshimi T, Nagura H. Urocortin expression in the human central nervous system. Clin Endocrinol (Oxf). 1999 Jan; 50(1):107-14. PMID: 10341863.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    201. Shimizu E, Kobayashi Y, Oki Y, Kawasaki T, Yoshimi T, Nakamura H. OPC-13013, a cyclic nucleotide phosphodiesterase type III, inhibitor, inhibits cell proliferation and transdifferentiation of cultured rat hepatic stellate cells. Life Sci. 1999; 64(23):2081-8. PMID: 10372650.
      Citations: 3     Fields:    Translation:AnimalsCells
    202. Iino K, Sasano H, Oki Y, Andoh N, Shin RW, Kitamoto T, Totsune K, Takahashi K, Suzuki H, Nagura H, Yoshimi T. Urocortin expression in human pituitary gland and pituitary adenoma. J Clin Endocrinol Metab. 1997 Nov; 82(11):3842-50. PMID: 9360550.
      Citations: 9     Fields:    Translation:Humans
    203. Iino K, Sasano H, Yabuki N, Oki Y, Kikuchi A, Yoshimi T, Nagura H. DNA topoisomerase II alpha and Ki-67 in human adrenocortical neoplasms: a possible marker of differentiation between adenomas and carcinomas. Mod Pathol. 1997 Sep; 10(9):901-7. PMID: 9310953.
      Citations: 20     Fields:    Translation:Humans
    204. Shigematsu N, Ito H, Oki Y, Kawada T, Suzuki T, Takeda A, Uematsu M, Kubo A, Fujii M, Kanzaki H. [Prognostic factors of nasopharyngeal carcinoma treated by radiotherapy]. Nihon Igaku Hoshasen Gakkai Zasshi. 1996 Dec; 56(14):1050-5. PMID: 9014467.
      Citations: 1     Fields:    Translation:HumansPHPublic Health
    205. Morishima I, Sone T, Mokuno S, Taga S, Shimauchi A, Oki Y, Kondo J, Tsuboi H, Sassa H. Clinical significance of no-reflow phenomenon observed on angiography after successful treatment of acute myocardial infarction with percutaneous transluminal coronary angioplasty. Am Heart J. 1995 Aug; 130(2):239-43. PMID: 7631601.
      Citations: 45     Fields:    Translation:HumansCTClinical Trials
    206. Shibata M, Oki Y, Iwata M, Ogasawara B, Chujoh C, Ikeda H, Itoh G, Noda A. A case of primary malignant lymphoma of the liver. Gastroenterol Jpn. 1991 Dec; 26(6):769-73. PMID: 1765251.
      Citations:    Fields:    Translation:Humans
    207. Sasaki M, Arai T, Usui T, Oki Y. Immunohistochemical, ultrastructural, and hormonal studies on the endocrine pancreas of voles (Microtus arvalis) with monosodium aspartate-induced diabetes. Vet Pathol. 1991 Nov; 28(6):497-505. PMID: 1685274.
      Citations: 4     Fields:    Translation:AnimalsCells
    208. Sasaki M, Arai T, Shiomi M, Ikeda H, Oki Y. Changes in plasma insulin and glucagon concentrations and hepatic enzyme activities in diabetic voles treated with monosodium aspartate. J Vet Med Sci. 1991 Jun; 53(3):541-2. PMID: 1653043.
      Citations:    Fields:    Translation:Animals
    209. Shirahige Y, Watanabe T, Oki Y, Sonoda T, Adachi I. A case of cervical carcinoma of the uterus presenting with hyperosmolar non-ketotic coma as a manifestation of ectopic adrenocorticotropic hormone syndrome. Jpn J Cancer Res. 1991 Jun; 82(6):710-5. PMID: 1649812; PMCID: PMC5918500.
      Citations: 2     Fields:    Translation:Humans
    210. Sasaki M, Arai T, Oki Y, Komeda K. An ultrastructural study on the pancreatic islet B cells in diabetic herbivorous voles. Vet Res Commun. 1991; 15(3):205-10. PMID: 1882514.
      Citations: 2     Fields:    Translation:AnimalsCells
    211. Sugawara M, Nakamura T, Ohizumi T, Oki Y. [Composition of milk and electrophoretic analysis of milk casein in herbivorous voles (Microtus montebelli)]. Jikken Dobutsu. 1990 Apr; 39(2):281-4. PMID: 2193815.
      Citations:    Fields:    Translation:Animals
    212. Watanabe T, Oki Y, Orth DN. Kinetic actions and interactions of arginine vasopressin, angiotensin-II, and oxytocin on adrenocorticotropin secretion by rat anterior pituitary cells in the microperifusion system. Endocrinology. 1989 Oct; 125(4):1921-31. PMID: 2551632.
      Citations: 2     Fields:    Translation:Animals
    213. Sakamoto M, Tanaka I, Oki Y, Ikeda Y, Nanno M, Yoshimi T. Atrial natriuretic peptide and vasopressin in human plasma. Peptides. 1988 Jan-Feb; 9(1):187-91. PMID: 2966344.
      Citations: 1     Fields:    Translation:Humans
    214. Complete surgical excision is essential for the management of patients with breast implant-associated anaplastic large-cell lymphoma. Journal of Clinical Oncology. 34:160-168.
    215. Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma. British Journal of Haematology.
    216. The role of gemcitabine and rituximab in the management of relapsed or refractory hodgkin lymphoma. American Journal of Hematology/ Oncology. 7.
    217. Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression. Blood Cancer Journal. 4.
    218. Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation.
    219. Allogeneic stem-cell transplantation in patients with cutaneous lymphoma. Annals of Oncology. 26:2490-2495.
    220. P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC/BCL2 expression in diffuse large B-cell lymphoma. Modern Pathology.
    221. Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma. Haematologica. 100:e272-e274.
    222. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. British Journal of Haematology.
    223. Dose-Adjusted EPOCH-R and Mid-Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS Involvement. British Journal of Haematology.
    224. Chemotherapy Response Assessment by FDG-PET-CT in Early-stage Classical Hodgkin Lymphoma. International Journal of Radiation Oncology Biology Physics. 97:333-338.
    225. Human Pathology. 60:160-166.
    226. Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma. Clinical Lymphoma, Myeloma and Leukemia. 16:122-128.
    227. Does Bleomycin Lung Toxicity Increase the Risk of Radiation Pneumonitis in Hodgkin Lymphoma?. International Journal of Radiation Oncology Biology Physics. 96:951-958.
    228. Atypical lymphoproliferative disorder-clinical and pathological features. Dermatology Online Journal. 22.
    229. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia [2]. Blood. 108:4291-4292.
    230. Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma. British Journal of Haematology.
    231. Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. Biology of Blood and Marrow Transplantation. 21:1914-1920.
    232. Embolisation to the fingers of both hands from aortic atheroma. Medical Journal of Australia. 180:31.
    233. Chronic myelomonocytic leukemia with nucleophosmin (NPM1) mutation. European Journal of Haematology.
    234. Erratum. Leukemia. 27:1792.
    235. Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2-microglobulin level in patients with diffuse large b-cell lymphoma. British Journal of Haematology. 175:290-299.
    236. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma. The Lancet Oncology.
    237. Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era. Annals of Oncology. 27:895-901.
    238. Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma. British Journal of Haematology.
    239. Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry. Leukemia and Lymphoma. 1-10.
    240. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma. The Lancet Oncology.
    241. Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma. Leukemia and Lymphoma.
    242. Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes. Annals of Oncology. 27:1317-1323.
    243. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. British Journal of Haematology. 171:726-735.
    OKI's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (716)
    Explore
    _
    Co-Authors (121)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _